文献速递关节外科

在预测关节置换术后生存率时使用竞争风险估计器有何影响:大型登记研究中生存率估计方法的比较

What Is the Effect of Using a Competing-risks Estimator when Predicting Survivorship After Joint Arthroplasty: A Comparison of Approaches to Survivorship Estimation in a Large Registry.
PubMed 文献 · Clin Orthop Relat Res · 2021-01-01

该研究基于澳大利亚骨科协会国家关节置换登记系统中2003年1月1日至2017年12月31日的531,304例全膝关节置换和274,618例全髋关节置换数据,比较标准Cox模型与两种竞争风险模型(病因特异性Cox模型和Fine-Gray模型)在预测关节置换术后翻修风险方面的表现。结果显示三种模型区分高低风险患者的能力几乎相同,但在75岁及以上患者中标准Cox模型高估翻修风险的程度大于竞争风险模型。作者结论认为,在开发预测关节置换远期翻修的模型时,若不采用竞争风险建模方法,将导致对监测期间死亡风险高的患者高估翻修风险。

要点

  • 三种模型区分高低风险患者能力几乎相同,全膝关节置换c-index均为0.64(95%CI 0.64至0.64),全髋关节置换均为0.66(95%CI 0.66至0.66)。
  • 75岁及以上患者中,标准Cox模型高估翻修风险的程度大于病因特异性Cox模型和Fine-Gray模型。
  • 即使极端情况下个体患者10年预测风险最大绝对差仅1.8%,可能对个体无重要意义。

核心结论

  • 开发预测关节置换远期翻修的模型时,不采用竞争风险建模方法将导致对监测期间死亡风险高的患者高估翻修风险。
  • 即使事件频率和竞争死亡风险均高的极端情况下,个体患者10年预测风险最大绝对差仅1.8%,可能对个体无重要意义。
  • 开发或使用风险预测模型时,研究者和临床医生应了解建模过程中竞争风险的处理方式,尤其是模型拟用于死亡风险高的人群时。

研究设计与样本

  • 研究比较标准Cox模型(将竞争风险视为删失事件)、病因特异性Cox模型和Fine-Gray模型的预测性能。
  • 模型训练和测试使用澳大利亚骨科协会国家关节置换登记系统中2003年1月1日至2017年12月31日记录的531,304例全膝关节置换和274,618例全髋关节置换数据。
  • 该登记系统为大型数据库,对2003年起澳大利亚所有髋膝关节置换具有近乎完整的捕获和随访。
  • 比较两种预测场景:全膝关节置换后10年全因翻修风险预测和全髋关节置换后假体周围骨折翻修预测。
  • 使用一致性指数、积分Brier评分和校准图比较校准度和区分度,并按年龄亚组比较观察与预测事件比例。

主要发现

  • 标准Cox模型和两种竞争风险模型区分高低风险患者能力几乎相同,全膝关节置换三种方法c-index均为0.64(95%CI 0.64至0.64),全髋关节置换均为0.66(95%CI 0.66至0.66)。
  • 所有模型在75岁以下患者中表现相似,但75岁及以上患者中标准Cox模型高估翻修风险的程度大于病因特异性Cox模型和Fine-Gray模型。
  • 对死亡竞争风险低的患者,标准Cox、病因特异性Cox和Fine-Gray模型的10年预测风险在全膝关节置换和全髋关节置换中相似。
  • 对死亡风险增高的假设89岁患者,全膝关节置换中病因特异性Cox模型翻修风险为0.83% vs 标准Cox模型1.1%,差异可忽略。
  • 对死亡风险增高的假设89岁患者,全髋关节置换中病因特异性Cox模型10年预测风险为3.4% vs 标准Cox模型5.2%,差异较大。

临床怎么用

  • 作者结论认为,开发预测关节置换远期翻修的模型时,不采用竞争风险建模方法将导致对监测期间死亡风险高的患者高估翻修风险。
  • 作者结论认为,即使极端情况下个体患者10年预测风险最大绝对差仅1.8%,可能对个体无重要意义。
  • 作者结论认为,开发或使用风险预测模型时,研究者和临床医生应了解建模过程中竞争风险的处理方式,尤其是模型拟用于死亡风险高的人群时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is increasing interest in the development of statistical models that can be used to estimate risk of adverse patient outcomes after joint arthroplasty. Competing risk approaches have been recommended to estimate risk of longer-term revision, which is often likely to be precluded by the competing risk of death. However, a common approach is to ignore the competing risk by treating death as a censoring event and using standard survival models such as Cox regression. It is well-known that this approach can overestimate the event risk for population-level estimates, but the impact on the estimation of a patient's individualized risk after joint arthroplasty has not been explored. QUESTIONS/PURPOSES: We performed this study to (1) determine whether using a competing risk or noncompeting risk method affects the accuracy of predictive models for joint arthroplasty revision and (2) determine the magnitude of difference that using a competing risks versus noncompeting risks approach will make to predicted risks for individual patients. METHODS: The predictive performance of a standard Cox model, with competing risks treated as censoring events, was compared with the performance of two competing risks approaches, the cause-specific Cox model and Fine-Gray model. Models were trained and tested using data pertaining to 531,304 TKAs and 274,618 THAs recorded in the Australian Orthopaedic Association National Joint Replacement Registry between January 1, 2003 and December 31, 2017. The registry is a large database with near-complete capture and follow-up of all hip and knee joint arthroplasty in Australia from 2003 onwards, making it an ideal setting for this study. The performance of the three modeling approaches was compared in two different prediction settings: prediction of the 10-year risk of all-cause revision after TKA and prediction of revision for periprosthetic fracture after THA. The calibration and discrimination of each approach were compared using the concordance index, integrated Brier scores, and calibration plots. Calibration of 10-year risk estimates was further assessed within subgroups of age by comparing the observed and predicted proportion of events. Estimated 10-year risks from each model were also compared in three hypothetical patients with different risk profiles to determine whether differences in population-level performance metrics would translate into a meaningful difference for individual patient predictions. RESULTS: The standard Cox and two competing risks models showed near-identical ability to distinguish between high-risk and low-risk patients (c-index 0.64 [95% CI, 0.64 to 0.64] for all three modeling approaches for TKAs and 0.66 [95% CI 0.66 to 0.66] for THA). All models performed similarly in patients younger than 75 years, but for patients aged 75 years and older, the standard Cox model overestimated the risk of revision more than the cause-specific Cox and Fine-Gray model did. These results were echoed when predictions were made for hypothetical individual patients. For patients with a low competing risk of mortality, the 10-year predicted risks from the standard Cox, cause-specific Cox, and Fine-Gray models were similar for TKAs and THAs. However, a larger difference was observed for hypothetical 89-year-old patients with increased mortality risk. In TKAs, the revision risk for an 89-year-old patient was so low that this difference was negligible (0.83% from the cause-specific Cox model versus 1.1% from the standard Cox model). However, for THAs, where older age is a risk factor for both death and revision for periprosthetic fracture, a larger difference was observed in the 10-year predicted risks for a hypothetical 89-year-old patient (3.4% from the cause-specific Cox model versus 5.2% from the standard Cox model). CONCLUSION: When developing models to predict longer-term revision of joint arthroplasty, failing to use a competing risks modeling approach will result in overestimating the revision risk for patients with a high risk of mortality during the surveillance period. However, even in an extreme instance, where both the frequency of the event of interest and the competing risk of death are high, the largest absolute difference in predicted 10-year risk for an individual patient was just 1.8%, which may not be of consequence to an individual. Despite these findings, when developing or using risk prediction models, researchers and clinicians should be aware of how competing risks were handled in the modeling process, particularly if the model is intended for use populations where the mortality risk is high. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Cuthbert AR, Graves SE, Giles LC, et al. What Is the Effect of Using a Competing-risks Estimator when Predicting Survivorship After Joint Arthroplasty: A Comparison of Approaches to Survivorship Estimation in a Large Registry. Clin Orthop Relat Res. 2021. PMID: 33105301. doi:10.1097/CORR.0000000000001533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。